Press Room

News / Oct 19, 2021

Hovione website wins Digital Communication Awards 2021!

Hovione.com wins GOLD for the best website in the Digital Communication Awards 2021

Hovione website wins Digital Communication Awards DCA 2021

? Hovione wins Best Website Award ?







 

DCA Hovione wins Award - Gold Winner 2021 for Best Website

 

Our website www.hovione.com has been distinguished with the Digital Communication Awards that reward outstanding online projects and campaigns.

 

Our website was ranked as one of the best of over 400 applications and was chosen as a GOLD winner by the jury members in the website category.

 

The new website project that was launched in February 2021 and was described as “100% responsive with a personalized, clean, vibrant design and it is also more inclusive. The content is accessible to visually impaired people who can understand visual content."

 

The new website also presents a chatbot that is ready to answer the first questions in a faster and trendy way. It helps to get closer and provide a better customer experience. The website is user-friendly and lives by our motto - In it for life.

Hovione.COM New Website

The Digital Communication Awards are open to companies and agencies, associations and NGOs, political institutions, and parties from all over the globe since 2011.

 

 

Learn more and find the full list of winners at Digital-Awards.eu









 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026